<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE ijbi.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>International-Journal-of-Biomedical-Investigation-ISSUE VOLUME Volume 2 ISSUE Issue 2</title>
<link>http://ijbi.edwiserinternational.com/rss-feed.php</link>
<description>
International-Journal-of-Biomedical-Investigation: VOLUME Volume 2 ISSUE Issue 2, July-Dec 2019
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>International-Journal-of-Biomedical-Investigation-ISSUE VOLUME Volume 2 ISSUE Issue 2</title>
<link>http://ijbi.edwiserinternational.com/rss-feed.php</link>
<url>http://ijbi.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>Identification-of-Proteins-Interacting-with-PCSK9-Using-a-Protoarray-Human-Protein-Microarray</title>
		<pubDate>25-Sep-2019</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/CgGOQ7.pdf</link>
		<author>Wooten-CJ-Krishnaji-ST-Melendez-QM-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Proprotein convertase subtilisin-kexin 9 (PCSK9) appears to be involved in multiple processes. A ProtoArray Human Protein Microarray was used to identify proteins interacting with biotinylated PCSK9. Fifteen novel proteins interacting with PCSK9 were identified using this technique.  Only two of these proteins, sterol carrier protein 2 and hepatoma-derived growth factor, related protein 3, have known functions. The identification of proteins that could affect the expression/function of PCSK9 is of great interest due to potential implications in personalized medicine for hypercholesterolemic patients. ]]>}</description>
		</item><item>
		<title>Antibacterial-Properties-of-Ficus-sycomorus-Bark-Extract-Against-Staphylococcus-aureus-and-Escherichia-coli</title>
		<pubDate>10-Jan-2020</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/9RzC0Y.pdf</link>
		<author>Masaiti-GC-Malambo-C-Hikaambo-C-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Objective: To investigate the antibacterial properties of Ficus sycomorus bark extract against Staphyloccocus aureus and Escherichia coli.Materials and methods: This was a cross-sectional laboratory-based experimental study in which Staphylococcus aureus and Escherichia coli were cultured in the laboratory. Varying concentrations of F. sycomorus aqueous and ethanolic extracts were tested for antibacterial activity using the disc diffusion method. The sensitivity of the tested microorganisms to aqueous and ethanolic plant extracts was shown by zones of inhibition after incubation. Results: Antibacterial activity was seen through zones of inhibition starting from 50 mg/ml upwards, with the zones of inhibition increasing as the doses increased. The highest observed zones of inhibition were seen with F. sycomorus 500 mg/ml for both aqueous and ethanolic extracts. A difference was however noted in that a larger zone of inhibition of 6.1mm was obtained with the 500 mg/ml ethanolic extract, as compared to the 5.0 mm observed with the aqueous extract of the same concentration, when tested against S. aureus. A 7.0 mm zone of inhibition was measured when 500 mg/ml F. sycomorus ethanolic extract was tested against E. coli whilst the 500 mg/ml aqueous extract resulted in a 6.8 mm zone of inhibition. Ciprofloxacin produced better antibacterial effects against S. aureus and E. coli with zones of inhibition of 7.5 mm and 10 mm compared to F. sycomorus extracts (p]]>}</description>
		</item><item>
		<title>Preparation-of-a-Functional-Rat-LDL-Receptor-Minigene</title>
		<pubDate>24-Feb-2020</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/EkcgrA.pdf</link>
		<author>Catherine-J-Wooten-and-Dayami-Lopez</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[The majority of the low-density lipoprotein (LDL) receptors present in the body are expressed in the liver. Therefore, plasma LDL levels significantly correlate with changes in the activity of the hepatic LDL receptor. Based on this, there is a need to understand the regulatory mechanisms that control the hepatic expression of the low-density lipoprotein (LDL) receptor. Herein, we have prepared a functional rat LDL receptor minigene construct that can produce mRNA after splicing. Sequence analysis suggests that this construct has the potential to code for a truncated version of LDL receptor protein. This minigene could be used as a research tool to identify small molecules, natural products, and regulators of the LDL receptor gene that could be developed into LDL receptor-specific activators for therapeutic use.]]>}</description>
		</item></channel>